Case report Fatal thrombosis with activated factor VII in a paediatric patient on extracorporeal membrane oxygenation

Bleeding remains a potential complication for patients requiring extracorporeal life support systems. Recombinant activated factor VII (rFVIIa) is one of the drugs used in controlling bleeding. Its use is generally found to be safe. We report a paediatric patient who developed fatal thrombosis with the use of rFVIIa whilst on extracorporeal membrane oxygenation and discuss the possible factors that lead to fatal thrombosis. Crown Copyright # 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

[1]  P. Innerhofer,et al.  Administration of Recombinant Activated Factor VII (NovoSeven) in Three Cases of Uncontrolled Bleeding Caused by Disseminated Intravascular Coagulopathy , 2007, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[2]  J. Dunning,et al.  Is recombinant activated factor VII useful for intractable bleeding after cardiac surgery? , 2006, Interactive cardiovascular and thoracic surgery.

[3]  A. Goldman,et al.  Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery , 2005, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[4]  S. Friess,et al.  Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation* , 2005, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[5]  H. Büller,et al.  Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review , 2005, Critical care medicine.

[6]  N. Key,et al.  Activated recombinant factor VII in cardiac surgery , 2005, Current opinion in anaesthesiology.

[7]  Dougald M Monroe,et al.  Safety profile of recombinant factor VIIa. , 2004, Seminars in hematology.

[8]  M. Al Douri,et al.  Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.